Edarbi

Chemical Nameazilsartan medoxomil
Dosage FormTablet (oral; 40 mg, 80 mg)
Drug ClassReceptor antagonists
SystemCardiovascular
CompanyArbor Pharmaceuticals
Approval Year2011

Indication

  • For the treatment of hypertension, either alone or in combination with other antihypertensive agents.
Last updated on 6/20/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Edarbi (azilsartan medoxomil) Prescribing Information.2020Arbor Pharmaceuticals LLC, Atlanta, GA